Join to View Full Profile
333 E Magnolia BlvdSte 103Burbank, CA 91502
Phone+1 818-848-1555
Fax+1 818-842-9323
Dr. Gevorkyan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Adventist Health White MemorialResidency, Internal Medicine, 1996 - 1999
Keck School of Medicine of the University of Southern CaliforniaClass of 1996
Certifications & Licensure
CA State Medical License 1997 - 2025
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Amazing Charts EHR, AmazingCharts, LLC, 2012-2013
Clinical Trials
- A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease Start of enrollment: 2013 Jan 01
- Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease Start of enrollment: 2014 Jun 01
- Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects Start of enrollment: 2016 Feb 18
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsPharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the(lateral thigh) muscles of healthy adult participants.Kelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, Herta Crauwels, Claudia Leemereise
Antimicrobial Agents and Chemotherapy. 2024-01-10 - 5 citationsFirst-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunte...Naoto Yamakawa, Fumitoshi Tago, Kenya Nakai, Yasumi Kitahara, Shingo Ikari
Clinical Pharmacology in Drug Development. 2023-04-01 - 12 citationsSafety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.Wei Yin, Fahimeh Mamashli, Derek L. Buhl, Polyna Khudyakov, Dmitri Volfson
British Journal of Clinical Pharmacology. 2021-07-31
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
